Kolleen Kennedy Net Worth

The estimated Net Worth of Kolleen T Kennedy is at least $9.71 million dollars as of 15 May 2024. Ms. Kennedy owns over 948 units of Varian Medical Systems stock worth over $25,828 and over the last 13 years she sold VAR stock worth over $6,137,517. In addition, she makes $3,546,280 as President - Proton Solutions Division and Chief Growth Officer at Varian Medical Systems.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Kennedy VAR stock SEC Form 4 insiders trading

Kolleen has made over 99 trades of the Varian Medical Systems stock since 2012, according to the Form 4 filled with the SEC. Most recently she exercised 948 units of VAR stock worth $15,675 on 15 May 2024.

The largest trade she's ever made was exercising 56,573 units of Varian Medical Systems stock on 1 June 2017 worth over $3,995,751. On average, Kolleen trades about 2,453 units every 35 days since 2011. As of 15 May 2024 she still owns at least 1,562 units of Varian Medical Systems stock.

You can see the complete history of Ms. Kennedy stock trades at the bottom of the page.

Kolleen Kennedy biography

Kolleen T. Kennedy serves as President - Proton Solutions Division and Chief Growth Officer of the Company. Ms. Kennedy served as Executive Vice President and President, Oncology Systems from September 2014 to September 2018, and was Senior Vice President and President, Oncology Systems from October 2011 to September 2014. From January 2006 through September 2011, Ms. Kennedy served as Vice President, Oncology Systems Customer Service and Support. Prior to that, Ms. Kennedy was the Company’s Vice President, Oncology Systems Marketing, Product Management and Engineering from September 2004 to January 2006. Prior to becoming Vice President, Ms. Kennedy served in various marketing management positions since she joined the Company in 1997. Ms. Kennedy holds a B.S. degree in Radiation Oncology and a B.S. degree in Psychology, both from Wayne State University, as well as an M.S. degree in Medical Physics from the University of Colorado.

What is the salary of Kolleen Kennedy?

As the President - Proton Solutions Division and Chief Growth Officer of Varian Medical Systems, the total compensation of Kolleen Kennedy at Varian Medical Systems is $3,546,280. There are 1 executives at Varian Medical Systems getting paid more, with Dow Wilson having the highest compensation of $9,446,300.

How old is Kolleen Kennedy?

Kolleen Kennedy is 60, she's been the President - Proton Solutions Division and Chief Growth Officer of Varian Medical Systems since 2018. There are 4 older and 8 younger executives at Varian Medical Systems. The oldest executive at Varian Medical Systems, Inc. is David Illingworth, 66, who is the Independent Director.

What's Kolleen Kennedy's mailing address?

Kolleen's mailing address filed with the SEC is C/O IPG PHOTONICS CORPORATION, 377 SIMARANO DRIVE, MARLBOROUGH, MA, 01752.

Insiders trading at Varian Medical Systems

Over the last 21 years, insiders at Varian Medical Systems have traded over $57,574,967 worth of Varian Medical Systems stock and bought 500 units worth $22,595 . The most active insiders traders include Kent J Thiry, Timothy E Guertin et Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of $181,124. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth $1,142,589.

What does Varian Medical Systems do?

Complete history of Ms. Kennedy stock trades at ICU Medical, IPG Photonics Corp et Varian Medical Systems

Varian Medical Systems executives and stock owners

Varian Medical Systems executives and other stock owners filed with the SEC include:

• Dow Wilson,
  Chief Executive Officer, Director
• Kolleen Kennedy,
  President - Proton Solutions Division and Chief Growth Officer
• Chris Toth,
  President, Chief Operating Officer
• R. Andrew Eckert,
  Independent Chairman of the Board
• Jeffrey Balser,
  Independent Director
• Judy Bruner,
  Independent Director
• Anat Ashkenazi,
  Independent Director
• Jean-Luc Butel,
  Independent Director
• Regina Dugan,
  Independent Director
• David Illingworth,
  Independent Director
• Phillip Febbo,
  Independent Director
• Michael Hutchinson,
  Senior Vice President, Chief Legal Officer
• Francis Facchini,
  President, Interventional Solutions Business
• Anshul Maheshwari,
  Vice President, Treasurer and Investor Relations
• Michelle Le Beau,
  Independent Director
• J. Michael Bruff,
  Chief Financial Officer, Senior Vice President - Finance
• Magnus Momsen,
  SVP, CAO, Corporate Controller
• Mark R Laret,
  Director
• Jose Baselga,
  Director
• John W Kuo,
  SVP, Gen Counsel and Secretary
• Gary E Jr Bischoping,
  SVP, Finance & CFO
• Susan L Bostrom,
  Director
• Timothy E Guertin,
  Director
• Clarence R Verhoef,
  SVP, Finance, Corp Controller
• Venkatraman Thyagarajan,
  Director
• Sunny Sanyal,
  SVP and President, ICB
• Robert H Kluge,
  Corporate Vice President
• Richard M Levy,
  President and CEO
• Ruediger Naumann Etienne,
  Director
• John Seely Brown,
  Director
• Erich R Reinhardt,
  Director
• Tai Yun Chen,
  VP and Corporate Controller
• David W Jr Martin,
  Director
• Steven A Leibel,
  Director
• Kent J Thiry,
  Director
• Allen S Lichter,
  Director
• Samuel Hellman,
  Director
• Crisanto C Raimundo,
  Corporate Controller
• Terry R Lautenbach,
  Director
• Joseph B Phair,
  VP Admin,Gen Counsel,Secretary
• Elisha W Finney,
  Corporate Vice President & CFO
• Kevin O'reilly,
  SVP, President of Oncology Sys